title: T-cell lymphoma: morphology, immunophenotype and clinical features.
abstract: The histology, immunophenotype and clinical presentation of 43 cases of T-cell lymphoma are described. Cases were classified into nine types; T-lymphocytic lymphoma (three), mycosis fungoides (six), Sézary syndrome (two), T-zone lymphoma (13), angioimmunoblastic lymphadenopathy (AIL)-like T-cell lymphoma (five), pleomorphic medium cell (one), large cell immunoblastic (four), large cell polylobated (five) and lymphoblastic (four). The patients comprised 26 males and 17 females aged between 15 and 86 years. The majority showed disseminated disease at the time of diagnosis (18 stage IV, nine stage III, five stage II, eight stage I and three cases not staged). Thirty-one patients showed lymph node involvement. Cutaneous involvement was a common finding (18 cases, 10 cases excluding mycosis fungoides and Sézary syndrome). Details of therapy and clinical follow-up were obtained in 37 cases. With simple chemotherapy only one complete response (7%, 1/16) was obtained. With aggressive therapy 48% (13/27) of patients showed complete responses. Twenty patients died during the follow-up period. Life table analysis showed a 58% probability of surviving 1 year and 36% probability of surviving 3 years. There was a significant difference in survival probability between low/intermediate-grade (lymphocytic, Sézary syndrome, mycosis fungoides and T-zone lymphoma including AIL-type) lymphomas and high-grade (large cell immunoblastic and polylobated and lymphoblastic) lymphomas (P less than 0.025). However, when survival of T-zone and AIL-like T-cell lymphoma was compared with survival of large cell immunoblastic and polylobated lymphomas no significant difference was detected. Age (less than 50 years) and stage I or II disease were associated with significantly better survival (P less than 0.005 and P less than 0.05).
authors.affiliation: Department of Pathology, University of Edinburgh Medical School, Scotland.
authors.forename: A S
authors.initials: AS
authors.lastname: Krajewski
authors.forename: M W
authors.initials: MW
authors.lastname: Myskow
authors.forename: P G
authors.initials: PG
authors.lastname: Cachia
authors.forename: D M
authors.initials: DM
authors.lastname: Salter
authors.forename: T
authors.initials: T
authors.lastname: Sheehan
authors.forename: A E
authors.initials: AE
authors.lastname: Dewar
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D008223:Lymphoma / Q000453:epidemiology / Q000276:immunology / Q000473:pathology*; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D010641:Phenotype; D012606:Scotland; D012751:Sezary Syndrome / Q000453:epidemiology / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology